KR102354664B1 - Medicament inhaler - Google Patents

Abstract

The present invention discloses a medicament inhaler. The present invention is configured so that when an asthma patient inhales a particulate drug, the drug is included in vaporized vapor, thereby allowing the drug to reach the asthma patient's lungs without loss, thereby preventing some of the drug from staying in the inhaler. Of course, it is to improve the drug inhalation efficiency of asthma patients while preventing excessive inhalation of the drug.

Description

Medicine inhaler {MEDICAMENT INHALER}

The present invention relates to a medicament inhaler, and more particularly, to a medicament inhaler that allows the inhaled particulate medicament to sufficiently reach the lungs while being contained in vaporized vapor when an asthma patient inhales the particulate medicament.

In general, as civilization develops, modern people suffer from diseases called civilization diseases such as bronchial asthma and atopy due to various pollution and pollution.

In order to increase mental and physical stability and immunity by solving the above problems, and to obtain the effect of promoting health and replacing the negative culture of our society such as tobacco, aroma or pharmaceuticals can be used anytime, anywhere, anytime and anywhere. A lot of research has been done on portable inhalers to obtain

That is, the use of an inhaled powder comprising an active substance is of particular importance, in addition to administering a bronchial active compound in the form of a metered aerosol and inhalable solution for the medicament inhaled by asthma patients.

Particularly in the case of active substances with high efficacy, only a small amount of the active substance per single administration is required to achieve a therapeutic effect. In this case, an inhalation powder is prepared by diluting the active substance with a suitable excipient.

Due to the large amount of excipients, the properties of the inhalation powder are greatly influenced by the choice of excipients. When choosing an excipient, its particle size is of particular importance. In general, the finer the excipient, the poorer its flow properties.

However, good flow properties when packaging and dividing individual doses of the formulation, e.g. when preparing capsules for powder inhalation, or when patient metering of individual doses prior to using a multi-dose powder inhaler is a necessary condition for very accurate weighing.

In addition, the particle size of the excipient is very important to the ejection properties of the capsule when used in an inhaler. It has also been found that the particle size of the excipient has a significant impact on the proportion of active substance in the inhaled powder delivered by inhalation. The term inhalation rate of an active substance refers to particles of inhaled powder that, when inhaled by breath, migrate deep into the branches of the lungs. The particle size required for this is 1 to 10 μm, preferably less than 6 μm.

However, in the conventional powder inhaler that injects fine powder into fine particles, when the particulate drug is inhaled, the inhaled particulate drug is not sufficiently inhaled to the lungs and a part of the drug remains in the inhaler. There was a problem in that asthma patients inhaled an excessive amount of medication in consideration of the loss.

Public Utility Model Publication No. 20-1999-0039904 (published on November 15, 1999) Registered Patent Publication No. 10-1281699 (date of publication 2013.07.03.) Laid-open Patent Publication No. 10-2016-0105800 (published on September 7, 2016) Laid-open Patent Publication No. 10-2018-0040379 (published on April 20, 2018)

The problem to be solved by the present invention is that when an asthma patient inhales a particulate drug, the drug is included in the vaporized vapor, so that the drug can reach the asthma patient's lungs without loss, so that a part of the drug is inhaled. An object of the present invention is to provide a medicament inhaler that prevents over-inhalation of the medicament as well as preventing it from staying in the medicament.

The drug inhaler, which is a means of solving the problems of the present invention, has a first storage space for accommodating a vaporization accelerating composition, a first vapor discharge passage, and a connection nozzle communicating therewith, the vaporization container having a derivative insertion hole provided on one side of the terminal; a derivative in close contact with or inserted into the derivative insertion hole to induce discharge of the vaporization promoting composition accommodated in the first storage space through a capillary phenomenon; an atomization unit for vaporizing the vaporization promoting composition induced by the derivative while generating heat when power is supplied; and a second storage space for accommodating the medicine for asthma patients, a second vapor discharge flow path, and an asthma patient suction contact in communication therewith, detachably connected to the connection nozzle, and through the suction contact, the asthma patient an inhalation container for inhaling the medicament into the lungs of the asthma patient while the medicament is contained in the vaporized vapor guided through the second vapor discharge path; Including, an external air inlet hole is formed at one end of the inhalation container, and in the second storage space in the inhalation container in which the external air inlet hole is formed, when the asthma patient inhales the drug through the inhalation contact port, the drug A cylinder for dispensing a medicament for pushing in the direction of the suction contact is to be formed.

In addition, the vaporization container may include a liquid injection valve for injecting the vaporization accelerating composition; will further include

In addition, the first vapor discharge passage is divided installed in the center of the vaporization vessel, or is formed along the inner peripheral surface of the vaporization vessel.

In addition, the derivative is prepared from any one of a multi-layered expandable nickel net, stainless fiber felt, polymer foam, metal porous body, and fiber, or a combination thereof.

In addition, the atomization unit, to be coupled to one end of the vaporization vessel, the atomization vessel is accommodated in the fixing plate to which the derivative is fixed; an electrode unit for supplying power that is spirally coupled in the atomization vessel; and a heating element that is formed on the outer surface of the derivative accommodated in the atomization container and generates heat to vaporize the vaporization promoting composition induced through the derivative according to the power supplied from the electrode part; will include

In addition, the electrode unit may include: an electrode body having an inlet communicating with the first vapor discharge passage, and a coupling screw portion fixed in electrical contact with the inner bottom surface of the atomization container having a hollow structure having both ends open; a negative electrode formed on one side of the electrode body and having electrical contact with the heating element; and a positive (+) electrode formed on one side of the electrode body and having electrical contact with the heating element; will include

In addition, the heating element is wound on the derivative while being connected to the electrode, and a filament-type heating wire having a coil structure made of a nickel alloy or a composite of a rare earth element may be used.

In addition, as the heating element, a high-frequency or ultra-high frequency generator connected to the electrode may be used, and in this case, the derivative is molded into a flat plate structure in close contact with the high-frequency or ultra-high frequency generator.

In addition, the heating element includes a Peltier element electrically connected in parallel to the electrode, and the heat absorbing plate of the Peltier element is in physical contact with the heating element.

In addition, the heating element is wound on the derivative while being connected to the electrode, and a filament-type heating wire having a coil structure made of a nickel alloy or a composite of a rare earth element and a high-frequency or ultra-high frequency generator are paralleled.

In addition, the vaporization promoting composition will be any one of general nutrients, minerals, vitamins, amino acids, and physiologically active agents.

In addition, the general nutrients include water, protein, lipid, carbohydrate, insoluble dietary fiber, soluble dietary fiber, total dietary fiber, and sugar, or inorganic calcium, phosphorus, iron, sodium, magnesium, manganese, zinc, cobalt, copper, molybdenum, selenium, fluorine, iodine, ash, calcium, phosphorus, iron, sodium, zinc any one or a combination of two or more; As a vitamin, any one or two of vitamin A, retinol (RE), beta-carotene, thiamine, riboflavin, niacin, vitamin C, vitamin B6, pantothenic acid, vitamin B12, folic acid, vitamin D, vitamin E, vitamin K, vitamin, thiamine or selected from a combination of the above; The amino acid is selected from isoleucine, leucine, lysine, methionine, cysteine, phenylalanine, tyrosine, threonine, tryptophan, valine, histidine, arginine, aspartic acid, glutamic acid, glycine, proline, serine, any one or a combination of two or more; As bioactive agents, daidzein, genistein, glycerine, cyanidin, delphinidin, malvidin, pelagonidine, phenonidine, peturidine, epicatechin, epicatechin 3-gallet, epicalocatechin, epicalocatechin 3- Gallet, catechin, gallocatechin, eriodicchol, hesperretin, naringenin, epiignin, luteolin, isohamnetin, kaempferol, mylycetin, quercetin, monomer proanthocyanidin, dimer proanthocy Anidine, trimer proanthocyanidin, 4-6 mer proanthocyanidin, 7-10 mer proanthocyanidin, polymer proanthocyanidin, choline, betanin, procholine, glycerophosphocholine, phospho It may be selected from any one of choline, phosphatidylcholine, and sphingomyelin or a combination of two or more.

The vaporization promoting composition, amino acid, gingko biloba (Gingko Biloba), coenzyme Q 10 (Co-Q10), Phosphatidyl Serine (PS), alpha lipoic acid (Alpha Lipoic Acid), inorganic salt, any one nutritional component of minerals class; Green tea, dunggula, omija tea, maekmundong tea, corn mustard tea, plum tea, tangerine peel tea, ginseng tea, chrysanthemum tea, sagebrush, quince, arrowroot, goji berry, cornus liana, persimmon leaf, duchung, oolong, and donggyuja tea; Any one of the fruit components of orange, lemon, and grapefruit; a vegetable component of any one of broccoli extract, cabbage extract, onion, garlic, ginger, lettuce extract, kale extract, bellflower extract, and tomato extract; Ginkgo biloba, bokbunja, goji berry, omija, saengsaja, tosaja, sansuyu, and any one oriental herbal ingredient; It will further include a group selected from one or a combination of two or more of the functional ingredients of any one of royal jelly, plum, heotgae tree, and xylitol.

delete

In addition, at the intersection point where the second vapor discharge passage and the second storage space meet, when the vapor vaporized through the second vapor discharge passage is discharged to the suction contact port, the drug is mixed with the vaporized vapor to be mixed to guide. The venturi tube is formed.

In addition, the suction container is disposable, and the external air inlet hole is sealed by a sealing tape when the suction container is not in use.

As described above, according to the present invention, when an asthma patient inhales a particulate drug, the drug is included in the vaporized vapor, and through this, the drug can reach the asthma patient's lungs without loss, so that a part of the drug is stored in the inhalation container. The effect of improving the drug inhalation efficiency of asthma patients can be expected while preventing excessive inhalation of the drug as well as preventing it from staying inside.

Effects of the present invention are not limited to the effects mentioned above, and other effects not mentioned will be clearly understood by those skilled in the art from the description of the claims.

1 is a combined perspective view showing the structure of a drug inhaler according to an embodiment of the present invention.
Figure 2 is an exploded perspective view showing the structure of the drug inhaler according to the embodiment of the present invention.
Figure 3 is a cross-sectional view showing the structure of the drug inhaler according to the embodiment of the present invention.

Hereinafter, embodiments of the present invention will be described with reference to the accompanying drawings.

1 is a combined perspective view showing the structure of a drug inhaler according to an embodiment of the present invention, FIG. 2 is an exploded perspective view showing the structure of a drug inhaler according to an embodiment of the present invention, and FIG. A cross-sectional view showing the structure is shown.

1 to 3 , the drug inhaler according to an embodiment of the present invention includes a vaporization container 10 , a derivative 20 , an atomization unit 30 , and an inhalation container 40 .

The vaporization container 10 is a first storage space 11 for accommodating the vaporization promoting composition, and when the vaporization promoting composition is vaporized by the atomization unit 30, the vaporized vapor is transferred to the inhalation container 40 A first steam discharge passage 12 for discharging, and a connection nozzle 13 communicating with the first steam discharge passage 12 are formed, as well as a derivative in which a part of the derivative 20 is inserted into one terminal side. The insertion hole 14 may be formed.

Here, the vaporization container 10 is provided with a liquid inlet valve 15 for injecting the vaporization accelerating composition, as well as the first vapor discharge passage 12 is partitioned into the center of the vaporization container 10, or It may be formed along the inner peripheral surface of the vaporization vessel (10).

That is, the vaporization vessel 10 is a hollow structure in which the first vapor discharge passage 12 is embedded in the center, and the periphery of the first vapor discharge passage 12 may have an integrated communication structure, In the communication structure, the derivative insertion hole 14 communicating with the outside may be provided.

Here, the vaporization promoting composition is harmless to the human body, and may be any one of general nutrients, minerals, vitamins, amino acids, and physiologically active agents.

The general nutrients include water, protein, lipid, carbohydrate, insoluble dietary fiber, soluble dietary fiber, total dietary fiber and sugar, or inorganic calcium, phosphorus, iron, sodium, magnesium, manganese, zinc, cobalt, copper, molybdenum, selenium, fluorine, iodine, ash, calcium, phosphorus, iron, sodium, zinc any one or a combination of two or more; As a vitamin, any one or two of vitamin A, retinol (RE), beta-carotene, thiamine, riboflavin, niacin, vitamin C, vitamin B6, pantothenic acid, vitamin B12, folic acid, vitamin D, vitamin E, vitamin K, vitamin, thiamine or selected from a combination of the above; The amino acid is selected from isoleucine, leucine, lysine, methionine, cysteine, phenylalanine, tyrosine, threonine, tryptophan, valine, histidine, arginine, aspartic acid, glutamic acid, glycine, proline, serine, any one or a combination of two or more; As bioactive agents, daidzein, genistein, glycerine, cyanidin, delphinidin, malvidin, pelagonidine, phenonidine, peturidine, epicatechin, epicatechin 3-gallet, epicalocatechin, epicalocatechin 3- Gallet, catechin, gallocatechin, eriodicchol, hesperretin, naringenin, epiignin, luteolin, isohamnetin, kaempferol, mylycetin, quercetin, monomer proanthocyanidin, dimer proanthocy Anidine, trimer proanthocyanidin, 4-6 mer proanthocyanidin, 7-10 mer proanthocyanidin, polymer proanthocyanidin, choline, betanin, procholine, glycerophosphocholine, phospho Choline, phosphatidylcholine, and sphingomyelin may be selected as any one or a combination of two or more.

In addition, the vaporization promoting composition, amino acids, gingko biloba (Gingko Biloba), coenzyme Q 10 (Co-Q10), Phosphatidyl Serine (PS), alpha lipoic acid (Alpha Lipoic Acid), inorganic salts, any one of minerals nutritional components; Green tea, dunggula, omija tea, maekmundong tea, corn mustard tea, plum tea, tangerine peel tea, ginseng tea, chrysanthemum tea, sagebrush, quince, arrowroot, goji berry, cornus liana, persimmon leaf, duchung, oolong, and donggyuja tea; Any one of the fruit components of orange, lemon, and grapefruit; a vegetable component of any one of broccoli extract, cabbage extract, onion, garlic, ginger, lettuce extract, kale extract, bellflower extract, and tomato extract; Ginkgo biloba, bokbunja, goji berry, omija, saengsaja, tosaja, sansuyu, and any one oriental herbal ingredient; It may further include a group selected from one or a combination of two or more of the functional ingredients of any one of royal jelly, plum, heotgae tree, and xylitol.

The derivative 20 is in close contact with or inserted into the derivative insertion hole 14 to induce the discharge of the vaporization promoting composition accommodated in the first storage space 11 through a capillary phenomenon, which is the vaporization vessel 10 . Alternatively, it may be fixed to the fixing plate 21 in which the air inlet hole 21a communicating with the first vapor discharge passage 12 is formed so as to divide the space inside the atomization part 30 into an internal space and an external space. .

In this case, the derivative 20 may be manufactured from any one of a multi-layered expandable nickel net, stainless fiber felt, polymer foam, metal porous body, and fiber, or a combination thereof.

Here, the derivative 20 can shorten the movement path of the vaporization promoting composition by directly contacting the vaporization promoting composition in the first storage space 11, which is a fluid movement due to viscosity when the vaporization promoting composition has a high viscosity. This is to prevent deterioration. On the other hand, there may be a gap between the derivative insertion hole 14 and the derivative 20 during the installation process, and there is a risk that the vaporization promoting composition stored in the first storage space 11 may leak due to this gap. have. Accordingly, by accommodating the fiber material in the interior of the first storage space 11, it is possible to prevent leakage of the vaporization promoting composition.

On the other hand, in the embodiment of the present invention, the terminal portion of the derivative 20 has been described as being inserted into the derivative insertion hole 14 of the vaporization container 10, but considering the risk of leakage of the vaporization promoting composition, not shown in the drawings However, as another embodiment of the present invention, the terminal end of the derivative 20 may be closely adhered or adhered to the derivative insertion hole 14 .

Since the derivative insertion hole 14 according to another embodiment of the present invention does not have a structure for inserting the derivative 20, it may be referred to as a communication groove. That is, the communication groove and the derivative insertion hole 14 have the same structure, but have different names depending on the purpose of use, and establishment of the technical concept of the communication groove used in the following description should be preceded.

As a result, according to another embodiment of the present invention, as a structure for the derivative 20 to be in close contact with the communication groove, the diameter size of the derivative 20 is designed to be larger than that of the communication groove, and then the The end portion of the derivative 20 is adhered to the outer periphery of the communication groove. Alternatively, the derivative 20 is designed to have a larger diameter than the communication groove, and then the derivative 20 is installed under pressure into the communication groove so that the vaporization promoting composition flowing out through the communication groove is absorbed into the derivative 20. it might be

The atomization unit 30 vaporizes the vaporization promoting composition induced by the derivative 20 while generating heat when power is supplied, and includes an atomization container 31, an electrode unit 32, a heating element 33, a power operation unit ( 34) is included.

The atomization vessel 31 is coupled to one end of the vaporization vessel 10 and the power operation unit 34 is coupled to the other end, and the fixing plate 21 to which the derivative 20 is fixed can be accommodated. will be.

The electrode part 32 is spirally coupled in the atomization container 31 and is configured to supply power to the heating element 33 .

That is, the electrode part 32 is in electrical contact with the inner bottom surface of the atomization container 31 having a hollow structure in which both ends are open and the suction port 321a communicating with the first vapor discharge passage 12 . A negative (-) electrode 322 and a positive (-) electrode 322 having an electrical contact with the heating element 33 on one side of the electrode body 321 and including an electrode body 321 having a coupling screw portion 321b fixed thereto It has an electrode 323 of +).

The heating element 33 is formed on the outer surface of the derivative 20 accommodated in the atomization container 31 , and promotes vaporization induced through the derivative 20 according to the power supplied from the electrode part 32 . It is exothermic to vaporize the composition.

At this time, the heating element 33 is connected to the electrodes 322 and 323 and wound on the derivative 20, and may be a filament-type heating wire having a coil structure made of a nickel alloy or a composite of a rare earth element. .

On the other hand, the heating element 33 may be a high-frequency or ultra-high frequency generator connected to the electrodes 322 and 323. In this case, the derivative 20 may be molded into a flat plate structure in close contact with the high-frequency or ultra-high frequency generator. there will be

In addition, the heating element 33 includes a Peltier element electrically connected in parallel to the electrodes 322 and 323, and the heat absorbing plate of the Peltier element may be configured to be in physical contact with the heating element 33 will be.

On the other hand, the heating element 33 is connected to the electrodes 322 and 323 and wound on the derivative 20, and a filament-type heating wire having a coil structure made of a nickel alloy or a composite of a rare earth element, and a high-frequency or ultra-high frequency To enable the generator to be parallel, or to include a Peltier element electrically connected in parallel to the electrodes 322 and 323, the heat absorbing plate of the Peltier element may be configured to be in physical contact with the heating element 33 will be.

The suction container 40 is detachably connected to the connection nozzle 12, and the second storage space 41 and the second vapor discharge passage 42 in which the asthma patient's medication is accommodated and the asthma patient inhalation communicating therewith It has a contact hole (43).

A medicament suitable for administration by such inhalation container 40 is a medicament dispensed by inhalation, for example, salbutamol, terbutaline, limiterol, fenoterol, lipoterol, adrenaline, pirbuterol, isoprenaline. , orciprenaline, bitolterol, salmeterol, formoterol, clenbuterol, procaterol, broxaterol, picumeterol, TA-2005, mabuterol, and pharmaceutically acceptable esters and salts thereof. β-adrenoreceptor agonists; anticholinergic bronchodilators such as ipratropium bromide; For example, glucocorticosteroids such as beclomethasone, fluticasone, budesonide, tipredane, dexamethasone, betamethasone, fluokinolone, triamkinolone acetonide, mometasone, and pharmaceutically acceptable esters and salts thereof ; antiallergic agents such as sodium cromoglycate and nedochromyl sodium; expectorant; colytics-free; antihistamines; cyclooxynase inhibitors; leukotriene synthesis inhibitors; leukotriene inhibitors; phospholipase-A2 (PLA2) inhibitors; platelet agglutinin (PAF) inhibitors and asthma prophylactics; antiarrhythmic drugs; stabilizator; cardiac glycosides; hormone; antihypertensives; antidiabetic drugs; anti-parasitic agent; anticancer drugs; sedative; painkiller; Antibiotic; antirheumatic agents; immunotherapy; antibacterial agents; antihypertensives; vaccine; antiviral agents; protein; polypeptides and peptides such as peptide hormones and growth promoters; polypeptide vaccines; enzyme; endorphins; lipoproteins and polypeptides involved in the blood coagulation cascade; vitamin; Other agents include, for example, cell surface receptor blockers, antioxidants, free radical scavengers, and organic salts of N,N'-diacetylcystine.

Accordingly, in the inhalation container 40, when the asthma patient inhales the medicine through the suction contact port 43, the medicine is contained in the vaporized vapor guided through the second vapor discharge path 42 and is lost. It can be inhaled into the lungs of asthmatics without

At this time, an external air inlet hole 44 is formed at one end of the suction container 40, and the second storage space 41 in the suction container 40 in which the external air inlet hole 44 is formed. When the asthma patient inhales the medicament through the inhalation contact port 43 , the medicament ejection cylinder 45 for pushing the medicament toward the inhalation contact port 43 can be formed.

On the other hand, at the intersection point where the second steam discharge passage 42 and the second storage space 41 meet, vapor vaporized through the second steam discharge passage 42 is discharged to the suction contact port 43 . A venturi tube (not shown) for guiding the drug to be mixed with the discharged vaporized vapor may be formed, the suction container 40 is disposable, and the external air inlet hole 44 is the suction container 40 ) can be sealed by a sealing tape (not shown) when not in use.

As such, the drug inhaler according to an embodiment of the present invention opens the liquid inlet valve 15 of the vaporization container 10 first, as in the accompanying FIGS. The storage space 11 is filled with a vaporization promoting composition.

After that, after filling the second storage space 41 of the suction container 40 with the particulate drug, the second vapor of the suction container 40 is discharged to the connection nozzle 13 on the tip side of the vaporization container 10 . While fitting the flow path 42 , the sealing tape is removed from the external air inlet hole 44 of the suction container 40 .

Next, when power is supplied to the atomization unit 30 formed at one end of the vaporization vessel 10, power is supplied to the heating element 33 through the electrode unit 32 in the atomization unit 30, the The heating element 33 vaporizes the vaporization accelerating composition guided to the derivative 20 to generate steam, and the vaporized steam passes through the air inlet hole 21a of the failure plate 21 to which the derivative 20 is fixed. It can be discharged to the second steam discharge passage 42 through the first steam discharge passage 12 and the connection nozzle 13 in the vaporization vessel 10 through the passage.

At this time, when the asthma patient bites the inhalation contact port 43 of the inhalation container 40 in their mouth and inhales the drug contained in the second storage space 41 in the inhalation container 40, the drug is transferred to the second While being mixed with the vaporized vapor discharged through the vapor discharge passage 42 , it is possible to reach the lungs of the asthma patient without loss through the suction contact port 43 .

That is, when the asthma patient inhales the drug through the inhalation contact port 43, external air flows into the external air inlet hole 44 formed at one end of the inhalation container 40, so that the inhalation container ( 40) The cylinder 45 for ejecting the medicine pushes the medicine accommodated in the second storage space 41 while linearly moving in the direction of the suction contact port 43 .

Then, the medicine pushed by the cylinder 45 can be mixed with the vaporized vapor discharged through the second vapor discharge passage 42, and the vaporized vapor with the medicine mixed in this way is the medicine for the asthma patient. It will all be delivered to the lungs.

Although the technical idea of the drug inhaler of the present invention has been described with the accompanying drawings, the most preferred embodiment of the present invention is exemplarily described and does not limit the present invention.

Therefore, the present invention is not limited to the specific embodiments described above, and without departing from the gist of the present invention as claimed in the claims, anyone with ordinary skill in the art to which the invention pertains can implement various modifications. Of course, such modifications are intended to be within the scope of the claims.

10; vaporization vessel 11; first storage space
12; a first steam discharge passage 13; connecting nozzle
14; derivative insertion hole 15; liquid inlet valve
20; derivative 21; fixed plate
21a; air inlet 30; fig
31; Atomization vessel 32; electrode part
321; electrode body 321a; intake
321b; mating thread 322; negative electrode
323; positive electrode 33; heating element
40; inhalation container 41; 2nd storage space
42; a second steam discharge passage 43; suction contact
44; outside air inlet 45; Cylinder for dispensing medicine

Claims (15)

It has a first storage space for accommodating the vaporization accelerating composition, a first vapor discharge passage, and a connection nozzle communicating therewith, a derivative insertion hole is provided on one side of the end, and a liquid injection valve for injecting the vaporization accelerating composition on one surface. a vaporization vessel provided;
a derivative in close contact with or inserted into the derivative insertion hole to induce discharge of the vaporization promoting composition accommodated in the first storage space through a capillary phenomenon;
an atomization unit for vaporizing the vaporization promoting composition induced by the derivative while generating heat when power is supplied; and,
It is detachably connected to the connection nozzle, and has a second storage space for accommodating a medication for an asthma patient, a second vapor discharge path, and an asthma patient inhalation contact port communicating therewith, wherein the asthma patient receives the medication through the suction contact port. an inhalation container in which the drug is contained in the vaporized vapor guided through the second vapor discharge path and inhaled into the lungs of an asthma patient upon inhalation; includes,
An external air inlet hole is formed at one end of the inhalation container, and the second storage space in the inhalation container in which the external air inlet hole is formed. A drug inhaler, characterized in that it forms a cylinder for ejecting the drug that is pushed in the spherical direction. The method of claim 1,
The first vapor discharge flow path is divided installed in the center of the vaporization container, or a drug inhaler, characterized in that formed along the inner peripheral surface of the vaporization container. The method of claim 1,
The derivative is a pharmaceutical inhaler, characterized in that it is prepared from any one of a multi-layered expandable nickel mesh, stainless fiber felt, polymer foam, metal porous body, and fiber, or a combination thereof. The method of claim 1,
The atomization unit,
an atomization vessel which is coupled to one end of the vaporization vessel and accommodates a fixing plate to which the derivative is fixed;
an electrode unit for supplying power that is spirally coupled in the atomization vessel; and,
a heating element that is formed on the outer surface of the derivative accommodated in the atomization container and generates heat to vaporize the vaporization promoting composition induced through the derivative according to the power supplied from the electrode part; A medicament inhaler comprising a. 5. The method of claim 4,
The electrode part,
an electrode body having an inlet communicating with the first vapor discharge passage, and a coupling screw portion fixed in electrical contact with an inner bottom surface of the atomization vessel having a hollow structure having both ends open;
a negative (-) electrode formed on one side of the electrode body and having electrical contact with the heating element; and,
a positive (+) electrode formed on one side of the electrode body and having electrical contact with the heating element; A medicament inhaler comprising a. 6. The method of claim 5,
The heating element is wound on the derivative while being connected to the electrode, characterized in that it is a filament-type heating wire having a coil structure made of a nickel alloy or a composite of a rare earth element. 6. The method of claim 5,
The heating element is a high-frequency or ultra-high frequency generator connected to the electrode, and the derivative is formed into a flat plate structure in close contact with the high-frequency or ultra-high frequency generator. 6. The method of claim 5,
The heating element includes a Peltier element electrically connected in parallel to the electrode, wherein the heat absorbing plate of the Peltier element is in physical contact with the heating element. 6. The method of claim 5,
The heating element is connected to the electrode and wound on the derivative, and a filament-type heating wire having a coil structure made of a nickel alloy or a composite of a rare earth element and a high frequency or ultra high frequency generator are used in parallel. The method of claim 1,
The vaporization promoting composition is a pharmaceutical inhaler, characterized in that any one of general nutrients, minerals, vitamins, amino acids, and physiologically active agents. 11. The method of claim 10,
The general nutrients include water, protein, lipid, carbohydrate, insoluble dietary fiber, soluble dietary fiber, total dietary fiber and sugar, or inorganic calcium, phosphorus, iron, sodium, magnesium, manganese, zinc, cobalt, copper, molybdenum, selenium, fluorine, iodine, ash, calcium, phosphorus, iron, sodium, zinc any one or a combination of two or more; As a vitamin, any one or two of vitamin A, retinol (RE), beta-carotene, thiamine, riboflavin, niacin, vitamin C, vitamin B6, pantothenic acid, vitamin B12, folic acid, vitamin D, vitamin E, vitamin K, vitamin, thiamine or selected from a combination of the above; The amino acid is selected from isoleucine, leucine, lysine, methionine, cysteine, phenylalanine, tyrosine, threonine, tryptophan, valine, histidine, arginine, aspartic acid, glutamic acid, glycine, proline, serine, any one or a combination of two or more; As bioactive agents, daidzein, genistein, glycerine, cyanidin, delphinidin, malvidin, pelagonidine, phenonidine, peturidine, epicatechin, epicatechin 3-gallet, epicalocatechin, epicalocatechin 3- Gallet, catechin, gallocatechin, eriodicchol, hesperretin, naringenin, epiignin, luteolin, isohamnetin, kaempferol, mylycetin, quercetin, monomer proanthocyanidin, dimer proanthocy Anidine, trimer proanthocyanidin, 4-6 mer proanthocyanidin, 7-10 mer proanthocyanidin, polymer proanthocyanidin, choline, betaine, procholine, glycerophosphocholine, phospho A pharmaceutical inhaler, characterized in that it is selected from any one or a combination of two or more of choline, phosphatidylcholine, and sphingomyelin. The method of claim 1,
The vaporization promoting composition, amino acid, Gingko Biloba (Gingko Biloba), coenzyme Q 10 (Co-Q10), Phosphatidyl Serine (PS), alpha lipoic acid (Alpha Lipoic Acid), inorganic salts, any one nutritional component of minerals class; Green tea, dung gully, omija tea, maekmundong tea, corn mustard tea, plum tea, tangerine peel tea, ginseng tea, chrysanthemum tea, quince, quince, arrowroot, goji berry, cornus liana, persimmon leaf, duchung, oolong, and donggyuja tea; Any one of the fruit components of orange, lemon, and grapefruit; a vegetable component of any one of broccoli extract, cabbage extract, onion, garlic, ginger, lettuce extract, kale extract, bellflower extract, and tomato extract; Ginkgo biloba, bokbunja, gugija, omija, saengsaja, tosaja, sansuyu, and any one oriental herbal ingredient; A pharmaceutical inhaler, characterized in that it further comprises one or a combination of two or more of the functional ingredients of any one of royal jelly, plum, heotgae tree, and xylitol. delete The method of claim 1,
At the intersection point where the second vapor discharge passage and the second storage space meet, when the vapor vaporized through the second vapor discharge passage is discharged to the suction contact port, a venturi pipe for guiding the drug to be mixed with the vaporized vapor discharged A medicament inhaler, characterized in that it forms a. The method of claim 1,
The inhalation container is disposable, and the external air inlet hole is sealed by a sealing tape when the suction container is not in use.

Images